New ECCO 2026 data explore whether subcutaneous infliximab can reliably recapture disease control after treatment interruption. Read the analysis.
Discover how Genentech’s Gazyva Phase III data could reshape treatment goals in membranous nephropathy and what regulators and clinicians will watch next.
Eli Lilly and Company (Lilly) announced that its selective RET inhibitor selpercatinib, marketed as Retevmo, achieved a highly statistically significant improvement in investigator-assessed event-free survival when used as adjuvant therapy in patients with stage II–IIIA RET fusion-positive non-small cell lung cancer, based on topline results from the Phase 3 LIBRETTO-432 trial. The study compared selpercatinib […]
DifGen Pharmaceuticals secures rare FDA approval for fluorometholone ophthalmic suspension. Find out why this complex generic matters for ophthalmology markets.
Centivax has begun Phase 1 testing of its universal flu vaccine Centi-Flu 01. Find out what this trial could change for influenza prevention.
Explore why vein health supplements like VenEase are gaining traction, what they change in circulation care, and the risks regulators and clinicians are watching.
Hoth Therapeutics secures a U.S. patent for exon-skipping allergy therapy. Read what this means for immunology strategy, clinical risk, and future drug development.
BioLife Solutions expands into cytokines through a Qkine agreement. Find out what this means for CGT manufacturing workflows and supplier strategy.
AstraZeneca’s KALOS and LOGOS trials highlight triple inhaler therapy gains in asthma. Explore what this means for guidelines and payers.
Alto Neuroscience completes Phase 2 enrollment for ALTO-101 in CIAS. Discover what the upcoming data could mean for precision psychiatry.